Johnson & Johnson and Bayer AG had agreed to settle over 25,000 US lawsuits over their cameo blood thinner Xarelto for a lump-sum of $775 million, court documents revealed on Monday, the 25th of March 2019. According to a post-hearing joint statement made by Johnson & Johnson and Bayer AG, the amount would be shared equally between the two companies who had been jointly developing the drug.
The settlement would resolve all pre-existing US lawsuit over Xarelto, which had been subject to being a cause of irreversible and uncontrollable bleeding leading several to severe injuries and even death among thousand of litigants.
Most of the accusers had accused the drug maker of failing to warn them of its severe bleeding risk, claiming that the injuries could be averted if doctors and patients would have been provided with adequate information.
In a statement on Monday, the 25th of March 2019, Bayer said that the company still believed that the claims were without merit. The company said in a statement, “However, this favorable settlement allows the company to avoid the distraction and significant cost of continued litigation”.
Besides, J&J had also issued a post-hearing statement saying that they continued to believe in Xarelto and its safety, however, the settlement might just be the right thing for doctors and patients. In fact, Xarelto has mostly been used for deep vein thrombosis, embolism and cardio vascular diseases for dissolving blood clots and had widely been used alongside aspirin in coronary artery diseases.